A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
Inclusion Criteria:
Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least,
Have an EASI score ≥16 at the screening and baseline
Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline
Have ≥10% BSA of AD involvement at the screening and baseline.
Exclusion Criteria:
Las, 35010, Spain
Kaohsiung Niao Sung Dist, 83301, Taiwan